摘要標(biāo)題

演示文稿詳情  (CDT)

抗體偶聯(lián)藥物

Shitara, K

Trastuzumab deruxtecan (T-
DXd) vs ramucirumab (RAM) +
paclitaxel (PTX) in second-line
treatment of patients (pts) with
human epidermal growth factor
receptor 2-positive (HER2+)
unresectable/metastatic gastric
cancer (GC) or
gastroesophageal junction
adenocarcinoma (GEJA):
Primary analysis of the
randomized, phase 3
DESTINY-Gastric04 study.

Abstract #LBA4002

Oral Abstract Session

31 May 2025

3:24pm

Tolaney, SM

Trastuzumab deruxtecan (T-
DXd) + pertuzumab (P) vs
taxane + trastuzumab +
pertuzumab (THP) for first-line
(1L) treatment of patients (pts)
with human epidermal growth
factor receptor 2–positive
(HER2+) advanced/metastatic
breast cancer (a/mBC): Interim
results from DESTINY-Breast09.

Abstract #LBA1008

Oral Abstract Session

2 June 2025

7:30am

Dent, R

Exploratory biomarker analysis
of trastuzumab deruxtecan (T-
DXd) vs physician's choice of
chemotherapy (TPC) in HER2-
low/-ultralow, hormone
receptor-positive (HR+)
metastatic breast cancer (mBC)
in DESTINY-Breast06 (DB-06).

Abstract #1013

Oral Abstract Session

31 May 2025

3:23pm

Levy, BP

TROPION-Lung02:
Datopotamab deruxtecan
(Dato-DXd) plus
pembrolizumab (pembro) with
or without platinum
chemotherapy (Pt-CT) as first-
line (1L) therapy for advanced
non-small cell lung cancer (aNSCLC).

Abstract #8501

Oral Abstract Session

1 June 2025

8:12am

Waqar, SN

First-line (1L) datopotamab
deruxtecan (Dato-DXd) +
rilvegostomig in advanced or
metastatic non-small cell lung
cancer (a/mNSCLC): Results
from TROPION-Lung04 (cohort 5).

Abstract #8521 

Poster Session

31 May 2025

1:30pm

腫瘤驅(qū)動因素和耐藥性

Turner, NC

Camizestrant + CDK4/6
inhibitor (CDK4/6i) for the
treatment of emergent ESR1
mutations during first-line (1L)
endocrine-based therapy (ET)
and ahead of disease
progression in patients (pts)
with HR+/HER2– advanced
breast cancer (ABC): Phase 3,
double-blind ctDNA-guided
SERENA-6 trial.

Abstract #LBA4

Plenary Session

1 June 2025

2:41pm

Lu, S

Savolitinib (Savo) combined
with osimertinib (osi) versus
chemotherapy (chemo) in
EGFR-mutant (EGFRm) and
MET-amplification (METamp)
advanced NSCLC after disease
progression (PD) on EGFR
tyrosine kinase inhibitor (TKI):
Results from a randomized
phase 3 SACHI study.

Abstract #LBA8505

Oral Abstract Session

1 June 2025

9:48am

Levy, BP

Efficacy and CNS results from
a randomized subset of the
phase 2 SAVANNAH study
comparing savolitinib (savo) +
osimertinib (osi) combination
with savo + placebo (PBO).

Abstract #8513

Rapid Oral Abstract Session

2 June 2025

8:06am

Chaft JE

Neoadjuvant (neoadj)
osimertinib (osi) ±
chemotherapy (CT) vs CT
alone in resectable (R)
epidermal growth factor
receptor-mutated (EGFRm)
NSCLC: NeoADAURA.

Abstract #8001

Oral Abstract Session

2 June 2025

3:12pm

免疫腫瘤學(xué)與雙特異性抗體

Janjigian, YY

Event-free survival in
MATTERHORN: a randomized,
phase 3 study of durvalumab
plus 5-fluorouracil, leucovorin,
oxaliplatin, and docetaxel
chemotherapy (FLOT) in
resectable
gastric/gastroesophageal
junction cancer (GC/GEJC).

Abstract #LBA5

Plenary Session

1 June 2025

3:13pm

Powles, T

Circulating tumor DNA (ctDNA)
in patients with muscle-invasive
bladder cancer (MIBC) who
received perioperative
durvalumab (D) in NIAGARA

Abstract #4503

Oral Abstract Session

1 June 2025

10:45am

Reck, M

Associations of post-surgical
MRD status with neoadjuvant
ctDNA dynamics, genomic
mutations, and clinical
outcomes in patients with
resectable NSCLC (R-NSCLC)
from the phase 3 AEGEAN trial.

Abstract #8009

Rapid Oral Abstract Session

1 June 2025

4:30pm

Barbie, DA

Clinical and molecular
characteristics of early
progressors (EPs) and long
-term progression-free survivors
(LTPs) from the phase 3
ADRIATIC trial of
consolidation durvalumab (D) vs placebo (P)
after concurrent
chemoradiotherapy (cCRT) in
limited-stage small-cell lung
cancer (LS-SCLC).

Abstract #8014

Rapid Oral Abstract Session

1 June 2025

5:12pm

Mayadev, J

Ultrasensitive detection and
tracking of circulating tumor
DNA (ctDNA) and association
with relapse and survival in
locally advanced cervical
cancer (LACC): Phase 3
CALLA trial analyses.

Abstract #5502

Oral Abstract Session

2 June 2025

8:48am

Westin, SN

Durvalumab plus
carboplatin/paclitaxel followed
by durvalumab with or without
olaparib as first-line treatment
for endometrial cancer:
Longitudinal changes in
circulating tumor DNA.

Abstract #5512

Rapid Oral Abstract Session

3 June 2025

8:30am

Erinjeri, JP

Outcomes by baseline tumor
burden using the 6-and-12
score in EMERALD-1: a phase
3 study of durvalumab (D) ±
bevacizumab (B) with transarterial
chemoembolization (TACE) in
embolization-eligible
unresectable hepatocellular
carcinoma (uHCC).

Abstract #4083
Poster Session

31 May 2025

9:00am

Cascone, T

Neoadjuvant durvalumab (D) +
chemotherapy (CT) + novel
anticancer agents and adjuvant
D ± novel agents in resectable
non-small-cell lung cancer
(NSCLC): Updated outcomes
from NeoCOAST-2.

Abstract #8046

Poster Session

31 May 2025

1:30pm

Zhou, J

First-line rilvegostomig (rilve)
plus chemotherapy (CTx) in
advanced biliary tract cancer
(BTC): Primary analysis of
GEMINI-Hepatobiliary substudy
2 Cohort A.

Abstract #4080

Poster Session

31 May 2025

9:00am

Xu, R

ARTEMIDE-Gastric01: a phase
3 randomized study of
rilvegostomig with
fluoropyrimidine and
trastuzumab deruxtecan (T-
DXd) as first-line (1L) treatment
for locally advanced or
metastatic HER2-positive
gastric or gastroesophageal
junction cancer (GC/GEJC).

Abstract #TPS4204

Poster Session

31 May 2025

9:00am

Mathias, C

ARTEMIDE-Lung03: a phase 3,
randomized, double-blind,
multicenter, global study of
rilvegostomig or
pembrolizumab in combination
with platinum-based
chemotherapy as first-line
treatment for patients with
metastatic non-squamous non-
small-cell lung cancer whose
tumors express PD-L1.

Abstract #TPS8653

Poster Session

31 May 2025

1:30pm

細(xì)胞療法

Yoo, C

RHEA-1: First-in-human (FIH)
study of AZD9793, a first-in-
class CD8-guided T cell-
engager (TCE) for glypican-3-
positive (GPC3+) advanced or
metastatic hepatocellular
carcinoma (HCC).

Abstract #TPS4215

Poster Session

31 May 2025

9:00am

Kim, TM

Safety and Efficacy of
AZD0486, a CD19xCD3 T-cell
Engager, in Relapsed or
Refractory Diffuse Large B-cell
Lymphoma.

Abstract #7046
Poster Session

1 June 2025

9:00am

Shadman, M

TITANium: An open-label,
global multicenter Phase 1/2
study of AZD5492, a first-in-
class subcutaneous CD8-
guided tri-specific T-cell
engager (TCE), in patients (pts)
with relapsed or refractory (r/r)
B-cell malignancies.

Abstract #TPS7091

Poster Session

1 June 2025

9:00am

Le Gouill, S

SOUNDTRACK-E: A Phase 1/2
Open-label Multicenter Study to
Evaluate the Safety and
Efficacy of AZD0486
Monotherapy or Combination
Therapy in Patients With
Mature B-cell Malignancies.

Abstract #TPS7083

Poster Session

1 June 2025

9:00am

罕見病藥物

Chen, AP

Efficacy and safety of
selumetinib in adults with
neurofibromatosis type 1 (NF1)
and symptomatic, inoperable
plexiform neurofibroma (PN):
Primary analysis of KOMET
(NCT04924608), a Phase 3,
international, randomized,
placebo-controlled study.

Abstract #3014

Rapid Oral Abstract Session

2 June 2025

8:00am